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Introduction: 
Ovarian cancer is the fourth leading cause of cancer mortality in women 
in North America and Western Europe. Although it strikes only one in seventy 
women, ovarian cancer is the leading cause of gynecologic cancer deaths. In 
fact, in most age groups, it is responsible for more cancer deaths than all other 
t-
forms of gynecologic cancer combined. 1 The reason for such high mortality rates 
despite a rather low incidence is due to the advanced stage of cancer at diagnosis. 
Stage I tumors, classified according to the International Federation of 
Gynecology and Obstetrics (FIGO), are confmed only to one or both ovaries. 
Patients with stage I disease have a cure rate approaching 90%, whereas tumors I that are no longer confmed to the female reproductive tract, stage ill or IV, 
confer a 5-year survival of only 20%.2 However, over 70% of women who 
develop ovarian cancer present with advanced disease, or disease that has spread 
outside of the pelvis. 3 
Theoretically, if ovarian cancer were detected at an earlier stage, a 
majority of deaths could be prevented. However, this theory assumes that all 
ovarian cancer passes from stage I to stage III and that intervention in high grade 
tumors is effective. High-grade tumors have poorly differentiated cellular 
components and usually confer a worse prognosis. Most research in recent years 
has focused on early detection. Researchers and clinicians have been searching 
for an ideal screening method for years. An ideal screening tool would allow 
physicians to detect cancer at an earlier stage and to increase patient survival due 
to earlier treatment. The gold standard for diagnosis is laparoscopy or 
2 
laparotomy, but surgery is an impractical method of screening, both in terms of 
cost and unacceptable risk to the patient. Until the early 1980's, the most 
effective method of screening was patient interview combined with bimanual 
rectovaginal pelvic examination. Most women remain asymptomatic until the 
disease has progressed to an advanced stage. Common symptoms include a 
feeling of abdominal fullness due to mass effect and ascites, shortness of breath 
due to pleural effusions, and a palpable abdominal mass. According to the NIH 
consensus conference on ovarian cancer, without symptoms, a bimanual exam 
has an inadequate sensitivity and specificity for a screening test. 1 
In the late 1970's, the tumor-associated antigen CA-125 was discovered, 
and in the early 1980's it began to be used to monitor the progress of therapy in 
patients already diagnosed with ovarian cancer. CA-125 is a glycoprotein of 
high molecular weight that is expressed by various tissue types including most 
epithelial ovarian tumors. It can be detected by a monoclonal antibody (OC 125) 
by radioimmunoassay in the serum of patients with epithelial ovarian 
carcinomas. By the mid 1980's, researchers were beginning to investigate the 
role CA-125 may have in screening women for ovarian cancer before the onset 
of clinically apparent disease. 
There are several known risk factors for ovarian cancer, including: 
advancing age, nulliparity, North American or Northern European descent, a 
personal history of specific cancers (endometrial, colon, breast), and a family 
history of ovarian cancer. Family history of ovarian cancer has the strongest 
correlation. For the female population in general, ovarian cancer affects 30 to 50 
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women per 100,000, with a lifetime prevalence of one in 70 women. This risk 
increases with the number of first degree relatives affected. A woman with one 
first-degree relative diagnosed with ovarian cancer has a lifetime risk of 5%, or 
one in 20. If two or more first-degree relatives are affected, lifetime risk rises to 
7%. For women with a hereditary ovarian cancer syndrome (i.e. BRCAl, 
BRCA2), lifetime risk approaches 40%.1 These women represent a very special 
population. 
This paper investigates the potential role CA-125 has in screening for 
ovarian cancer. Specifically, it examines the specificity ofCA-125 as a 
screening tool for ovarian cancer in the general population, without specifically 
looking at women with other risk factors. Since there are no adequate means of 
screening short oflaparotomy, as discussed above, there is no comparison to 
other screening methods. The outcome measured is simply detection of ovarian 
cancer. No other interventions will be discussed. 
Methods: 
First, a search of the literature was performed. The primary sources were 
MEDLINE, EMBASE, and the Cochrane database. The data banks were 
searched with key words "ovarian cancer", "CA-125", "screening", and various 
combinations of these terms. Pertinent articles were then located. The 
references of these articles were scanned for any papers not uncovered by the 
searches. Appropriate articles were located and evaluated for inclusion. The 
results of the literature search are sununarized in Table 1. 
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The inclusion criteria for studies were explicit. First, studies had to 
evaluate the efficacy of CA-125 use alone, without other screening modalities. 
Secondly, outcome had to be measured as specificity and specificity and/or 
positive predictive value of CA-125 in detecting disease. Next, only studies 
dealing with the general female population were considered. Neither studies of 
women with familial ovarian cancer syndromes, nor studies of women at 
increased risk of developing ovarian cancer were included. 
Although it is widely regarded that randomized clinical trials produce the 
best data, the investigation of CA-125 as a screening tool does not readily 
accommodate such a study design. Due to the rather low incidence and 
b 
prevalence of this disease, it is necessary to enroll many hundreds of women to i 
create a large enough cohort with disease to find results of sufficient power to be 
clinically and statistically significant. The enrollment of thousands of women in 
a randomized control trial (RCT) would be daunting. Also, the study question 
does not lend itself well to such a study design. The gold standard for diagnosis 
of ovarian cancer is invasive surgery, be it laparotomy or laparoscopy. A 
comparison of CA-125 to laparotomy would be unethical, because asymptomatic 
women should not undergo invasive surgery for screening purposes. A 
randomized trial could be performed by following two large cohorts of women 
randomized to screening versus no screening and comparing the cancer 
diagnoses and outcomes, but the study would take many years and many dollars 
to perform. Comparison to screening via rectovaginal bimanual exam is 
possible. However, no studies have compared the two screening modalities in an 
RCT. Prospective cohort studies are the best means available for studying the 
problem at hand. 
For this evaluation, no RCT's were found for the review, so prospective 
and retrospective cohort studies and case-control studies were included. All 
review articles, overview articles, and prevalence studies were excluded. 
Additionally, abstracts alone were not accepted. A full reporting of the data was 
required. No study was included more than once. Relevant studies published in 
languages other than English were excluded. 
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After the inclusion and exclusion criteria were established, each article 
was read. An initial determination of acceptance was made as each article was 
read with the specific criteria for inclusion and exclusion at hand in the form of a 
checklist. The articles remaining for inclusion were then read a second time to 
assure that no exclusion criteria were missed. The author was the sole reviewer. 
A total of five articles met inclusion criteria for this review. Most articles were 
excluded, because they evaluated other screening modalities in combination with 
serum CA-125levels 
The articles were then further analysed to assess the validity of the study 
design and reporting. Each article was assessed via the ST ARD criteria as 
published in the Annals of Internal Medicine.4 Every article was reviewed and 
compared to the checklist of twenty-five suggested criteria. The results of the 
analysis of each article is reviewed below. 
Selected Studies: 
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The search methods and selection criteria lead to the inclusion of five 
studies.2•5•6•7•8 The first study assessing the potential ofCA-125 to predict the 
development of ovarian cancer was performed by Zurawski, et.al.5 and published 
in the International Journal of Cancer in 1988. This study was a case-control 
study conducted in 1986 in Norway. The investigators used the JANUS serum 
bank, which had blood samples from 39,300 women. Time from sample donated 
to the study intervention ranged from 1-143 months. The women were Red 
Cross blood donors. Otherwise, no mention of the selection criteria for serum 
donation was made. Serum samples were matched to names in the Norwegian 
Cancer Registry to find cases of ovarian cancer diagnosed between 1974-1986. 
105 cases were found among the 39,300 women who donated blood. Controls 
were also drawn from the JANUS serum bank and were matched by age, 
residence, time of collection, and conditions of storage. Three or four were 
drawn for each case, providing 323 matched controls. Serum samples from cases 
and controls then underwent radioimmunoassay (RIA) for the detection of CA-
125, and the results from cases and controls were compared. The technician was 
masked as to case or control status. This study met nineteen of the twenty-five 
STARD criteria for internal validity. 
A similar study was conducted by Helzlsouer, et.al.6 and published in 
1993 in JAMA. It was also a retrospective cohort study utilizing previously 
collected serum samples evaluated for CA-125 and compared to a cancer 
registry. This study was conducted in Washington County, Maryland. Serum 
samples were collected over a four-month period in 1974 from 20,305 residents. 
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Again, no selection criteria for donors were included. 11,009 women over the 
age of 18 donated serum to the study. Each subject completed a brief 
questionnaire of demographic information. In 1989, the women who donated 
samples were matched to cases of ovarian cancer in the Washington County 
cancer registry. Among the original 11,009 women, forty cases of ovarian 
cancer were detected. Time from blood donation to cancer diagnosis ranged 
from 1-15 years. Two controls were drawn from the remaining non-diseased 
subjects for each case. Controls were matched by age, race, menopausal status, 
time of day blood sample was collected, number of years since last menstrual 
period for menopausal women, and number of days since last menstrual period 
for premenopausal women. Three cases and seven controls were excluded at this 
time due to inadequate matching of time since last menstrual period, leaving 3 7 
cases and 73 controls. Serum samples were then assayed for CA-125 levels. 
The technician was masked to case or control status. This study met seventeen 
of the twenty-five STARD criteria. 
The third study to be evaluated is a prospective cohort study performed 
by Einhorn, et.a/.2 and published in Obstetrics & Gynecology in 1992. In this 
study, the investigators recruited 5550 women in Sweden aged 40 and older 
between January 1986 and February 1988. These women were randomly 
selected from the Stockholm Population Registry. Selection criteria were not 
available. CA-125levels were drawn on all subjects. For the frrstphase ofthe 
study, 35 U/mL was the upper limit of normal, and for the second phase of the 
study, 30 U/mL was the upper limit. A total of 175 women were identified as 
8 
having elevated CA-125. These women were placed in an intensive surveillance 
group. A control group was drawn from the population of women without 
elevated CA-125. Controls were matched by age. These 350 women had CA-
125 levels determined every three months and a transabdominal ultrasound and 
pelvic exam performed every six months by two of the authors. The authors 
f.--
were blinded as to CA-125levels, so management was based on clinical fmdings 
alone. Technicians performing the RIAs were blinded as to the subjects' case or 
control status. The remaining 5200 women in the study population underwent a 
second CA-125 radioimmunoassay 12 months after emollment. Ovarian cancer 
was detected in six of the women with elevated CA-125levels (6/175), no cases 
of ovarian cancer were detected in the control population (01175), and three other 
ovarian cancers, reported in the Tumor Registry and confirmed by histologic 
samples, were detected in the remaining women (3/5200). This study met 
seventeen of the twenty-five ST ARD criteria for internal validity. 
The fourth study evaluated in this paper is an investigation performed by 
Jacobs, et.al. 7 and published in 1996 by the British Medical Journal. This study 
was a prospective cohort study performed to determine the risk of developing 
ovarian cancer based on CA-125 level. The authors recruited 22,000 women 
volunteers aged 45 and greater between June 1986 and May 1990 via media 
publicity and job place announcements. 21,961 of these women were eligible for 
the study and underwent a CA-125 RIA. Of these women, 11,085 were 
randomly selected to undergo annual prevalence screening. Subsequently, 9344 
of these women were found to be eligible and chose to come in yearly for a 
9 
screening test. Inclusion criteria included age greater than 45 and amenorrhea 
for at least one year. Women with a history of bilateral oopherectomy or ovarian 
cancer were excluded. The screening protocol consisted of a venopuncture for 
determination ofCA-125. Women with levels above 30 U/mL were asked to 
return to the clinic for an ultrasonographic exam. Women with an abnormal 
ovarian volume, defined as greater than 8.8 mL, were referred for surgical 
evaluation. The remaining 10,876 women who were not randomly chosen for 
annual prevalence screening were sent a questionnaire by mail annually during 
the study period. Only 2.9% of the volunteers failed to complete an annual 
questionnaire. The median follow-up period was 6.68 years with a mean of 6.76 
years and a range of 4.67-9.13 years. During this time, forty-nine cases of 
ovarian cancer were detected from the original women found eligible for the 
study (49/21,961). This study met nineteen of the STARD criteria. 
The final study included in this review was a prospective cohort study 
performed by Zurawski, et.al. 8 and published in Gynecologic Oncology in 1990. 
This study was very similar to the one performed by Jacobs, et.al. Zurawski and 
his colleagues enrolled 1 082 women over the age of 40. They were selected 
from a population of people receiving an annual physical exam at the AMRAB, 
Sophiahemmet in Stockholm, Sweden. A CA-125 RIA was performed on all of 
the women. 36 women were found to have elevated levels, defined as greater 
than or equal to 35 U/mL. These thirty-six women and an age-matched control 
group were selected for follow-up, which included a CA-125 RIA every three 
months and a pelvic exam every six months. Transabdominal or transvaginal 
10 t---
ultrasound was performed as indicated based on the physical exam. The 
physicians performing the physical exams were masked as to CA-125 level. 
Technicians performing the CA-125 assays were blinded as to the subject's case 
or control status. One case of ovarian cancer was diagnosed among the cohort 
with elevated CA-125 levels (1136). No cases were detected in the control 
cohort. At the end of the study, the Stockholm Tumor and In-patient Registry 
was searched for any entries among the study participants. None of the original 
study population was lost to follow-up. This study met twenty of the twenty-five 
ST ARD criteria for internal validity. ~-
t 
Results: i 
The results of each study are summarized in Table 2. All of the studies 
found specificities above 90% for CA-125 in detecting ovarian cancer. It is 
important to notice the increasing specificities found in the prospective studies in 
which serial CA-125 assays were performed. This trend is expected, as serial 
testing always improves specificity. In fact, improving the specificity ofCA-125 
in the detection of ovarian cancer was one of the stated goals for the prospective 
studies as the earlier retrospective studies with only one CA-125 determination ' f 
had rather poor specificities. Also, CA-125 measurements were taken closer to 
the time of diagnosis in the prospective studies than in the retrospective studies. 
One important point to keep in mind when reviewing the articles is that women 
who had initial negative screens, or CA-125 below the designated level, were not 
retested as frequently or as many times as the initial women with positive 
II 
screens. By essentially ignoring the negative group, your specificity should 
certainly rise. 
Einhorn, et.a/.2 found a decreasing CA-125 level with increasing age 
regardless of which reference level was used. They found elevated levels (2: 35 
U/mL) in 69 of 1260 women (5.5%) younger than 50 years, and 71 of 4290 
women (1.6%) older than 50. This would suggest that older women may have 
fewer false positive results making them a more appropriate population to screen 
, especially when combined with the results of the scan of the Tumor Registry. 
Six ovarian carcinomas were found among the cases. All six of these women 
were older than age fifty, so the investigators chose to look at specificities 
according to age. CA-125 had specificities of97% and 98.5% in women over 
the age of 50 for cutoff levels of 30 and 35 UlmL respectively. These 
percentages drop to 91% and 94.5% for women below the age of 50. Helzlsouer, 
et. al. 6 also found a difference in specificity by stratifYing the study population. 
This study examined specificity based on menopausal status. The specificity of 
post-menopausal women was significantly higher than for premenopausal 
subjects. These results are sununarized in Table 3. 
Jacobs, et.al. 7 found that the risk for developing ovarian cancer increased L 
with the level ofCA-125 detected. One year after a CA-125level of greater than 
or equal to 30 U/mL, greater than or equal to 50 U/mL, and greater than or equal 
to 100 U/mL, a risk of 0.026, 0.083, and 0.149 respectively were found. The 
investigators were trying to determine whether CA-125 could be used as a 
predictor for disease rather than as a screening tool. They found powerful 
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evidence that the higher a woman's CA-125level, the greater the risk she has of 
developing ovarian cancer within the following year. 
Discussion: 
Two of these studies evaluated retrospective serum samples that had been 
collected years prior to the investigation. 5•6 Some of the cases were diagnosed 
greater than five years after the serum sample was obtained. It is not expected 
that CA-125 levels would be significantly elevated five years prior to diagnosis. 
±:-:;: __ 
Lower CA -125 values prior to cancer diagnosis would lead to lower specificity r 
and sensitivity when analyzing the data. More accurate results would be 
expected had blood samples been taken closer to the time of diagnosis. 
Zurawski, et.al. (1988) evaluated the cases for median value ofCA-125 based on 
the years prior to ovarian cancer detection. 5 These women had a lower average 
CA-125 level, as shown in Table 4. This could have biased the results toward 
L 
the null. The data in Table 4 suggest that the CA-125level increases as the time L 
to diagnosis shortens. This is a major problem with retrospective studies--there 
is no opportunity to observe the change in CA-125 over time. 
Several other areas of bias exist in the retrospective studies of Zurawski, 
et. al. 5 and Helzlsouer, et. al. 6 In both studies, the study population consisted of 
women who voluntarily donated blood, therefore introducing the possibility of 
volunteer bias, or subject self-selection. No random selection process was 
utilized. There is no way to know how this might affect the study results. One 
could postulate that women who donate blood are healthier. Women with 
13 
undiagnosed ovarian cancer (and potentially elevated CA-125) may not feel well 
enough to donate blood. Therefore, the results of the study would be biased 
toward the null. However, due to the small incidence of ovarian cancer, using 
these preexisting databases was a good way to find a study population with a 
significant number of subjects with the disease of interest. Also, the use of these 
databases saved time and expense for the investigators, but there was a definite 
trade-off with the introduction of volunteer bias. 
Also, Helzlsouer, et. al. 6 used blood samples from a collection campaign 
and then found local cases of cancer in a separate tumor registry for the same 
local area. There is no indication that all of the women who initially donated t 
blood still live in the area. Women who later developed ovarian cancer could 
easily have moved out of the area, thus affecting the final results of the study. 
i 
Three prospective cohort studies were evaluated as well.2•7•8 As discussed 
previously, this is the best study design located for evaluating the efficacy of 
CA-125 as a screening tool. Investigators have eliminated some of the problems 
associated with the retrospective study. They were able to assess serial CA-125 
determinations on each study subject, thus eliminating the time lag between 
sample collection and ovarian cancer detection. Also, cases and controls 
underwent additional testing in the form of pelvic exams and transabdominal 
ultrasounds, which are the traditional method of detecting ovarian cancer. This 
may increase confidence in the disease-free designation. 
In most of the studies, there was no way of knowing if the controls were 
disease free, as no definitive procedures were performed. The gold standard for 
14 
diagnosing ovarian cancer is invasive surgery. Not only is it unethical to perform 
laparotomies on asymptomatic controls, it would be exceedingly difficult to fmd 
any healthy subjects willing to undergo surgery. If women with unconfmned 
ovarian cancer were used as controls, this could affect the results in either 
direction. If the undiagnosed controls had elevated levels ofCA-125, this would 
bias the results toward the null by underestimating the difference between cases 
and controls. If undiagnosed controls had normal levels of CA-125, cases would 
have inflated CA-125 levels, thus overestimating the difference between the two 
groups. It has to be assumed that this problem is of very small significance as 
the incidence of ovarian cancer in the general population is very small. 
Another problem inherent in the type of studies performed concerns the 
use of tumor and cancer registries. The authors assume that all cases are 
registered. This may not be the case. Einhorn, et.al. 2. was the only study to 
address this potential source of bias. The authors report that entries in the 
Norwegian Tumor Registry have been proven "to be accurate in 98% of cases."2 
If this remark is taken at face value, it can be assumed that virtually no woman 
(2%) with diagnosed malignancy would be omitted from this list, which would 
reduce the effect of detection bias. 
It is also important to assess the internal validity of the studies based on 
San dar's criteria. All of the investigators used blinding where possible. The 
technicians performing the CA-125 assays were all blinded as to clinical status of 
the subject. All the physicians performing the physical exams were masked as to 
the patients' CA-125levels. 
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Another important consideration is the reproducibility of the results. 
Table 2 lists the specificities of each study and the positive predictive value if 
reported. The results are all very similar, lending credibility to the results. 
A final problem with these studies is the small number of cases. 
Individually, the studies found as few cases as one.8 Ovarian cancer incidence is 
so low that it is difficult to enroll enough women to detect a larger number of 
index cases. Although the results are significant in each study, clinical relevance 
is not clear-cut. A multicenter prospective study might allow the identification 
of enough cases of ovarian cancer to ensure adequate confidence in the results. 
A meta-analysis is required to combine all of the study results evaluated in this 
paper. Such an analysis is beyond the scope of this paper. 
These studies indicate that there is a positive correlation between CA-125 
levels and the later development of ovarian cancer. Specificities were uniforruly 
in the mid-nineties. High specificities are usually desired for screening protocols 
in order to reduce the number of false positive results. However, in the case of 
ovarian cancer, these specificities were not high enough. The only gold standard 
diagnostic test for ovarian carcinoma is invasive surgery. Even with specificities 
of99%, an unacceptable number of unnecessary surgeries would be performed if 
widespread screening were adopted. For example, Jacobs, et. al.7 reported a 
positive predictive value of3.1 %. This means 32 healthy women would have to 
have to undergo more invasive testing to find one woman with cancer. Current 
investigations are finding an improved specificity when several screening 
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modalities-such as transvaginal ultrasonography, serial CA-125 measurements, 
and other serum markers-are combined.9•10 This is an area of intensive research. 
As stated previously, serial testing as performed in the prospective 
studies caused an increase in specificity. Women with elevated levels ofCA-125 
were followed very closely at frequent intervals. If women with normal CA-125 
levels were not followed with the same level of scrutiny, it could lead to missed 
diagnoses of ovarian cancer, thus further introducing bias in the form of 
surveillance bias. The specificity of elevated CA-125levels would be artificially 
raised in comparison with other screening modalities (i.e. physical exam). 
Also, sensitivity and positive predictive value were very low. Sensitivity 
could be improved by lowering the threshhold value ofCA-125 considered to be 
abnormal, but doing so would lower specificity. Conversely, if the threshold 
value of CA -125 was raised, specificity would improve at the expense of 
lowering sensitivity. Then the risk would exist of missing cancer diagnoses 
altogether. Predictive value is based not only on sensitivity and specificity, but 
prevalence of disease. Even a very specific test will have a low positive 
predictive value if the disease is rare. 
A major weakness in the literature involving the use of CA-125 as a 
screening tool for ovarian cancer is that there is virtually no data on the 
effectiveness of the intervention. In none of these studies was there any proven 
benefit to detecting cancers early. Although several of the studies describe 
tumors found at Stage I, none of the studies included survival information on the 
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subjects. Also, there is no cost-effectiveness data. The papers reviewed assessed 
the specificity ofCA-125, rather than the outcome. 
In summary, while elevated CA-125 is indeed a risk factor for the 
development of ovarian cancer, its efficacy as a screening test is fairly poor. f--
Before screening their own patients solely with CA-125levels, physicians should 
evaluate them for other factors which put them at risk, such as family history, 
physical exam findings, and reported symptoms as a combination of modalities is 
proving to be a more specific means of screening. After that, should the 
physician choose to perform a CA-125 radioimmunoassay, the results should be 
interpreted in the context of the rest of the history and physical findings. Further 
investigation with imaging studies should then be undertaken in those women 
with elevated levels, such as pelvic ultrasound or MRI. CA-125 can be a 
powerful tool in helping to find ovarian cancer but cannot be used alone to make 
l the diagnosis. 
r 
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Table I Results of Literature Search 
Description 
Medline key word searches 
Search 1, CA125 
Search 2, ovarian cancer diagnosis 
Search 3, screening 
Combine 1 AND 2 (OR 3) and LIMIT by {participant 
types humans) 
Exclusion criteria* 
Multimodal screening investigated 
Did not report data for the outcome of interest 
(specificity ofCA-125 for detecting ovarian cancer) 
Review articles 
Only specialized population investigated 
Editorial or comment piece 
Not in English 
Total articles excluded 
Articles included from manual searches of bibliographies 
Total studies of interest 
EMBASE keyword searches 
Search 1, CA125 
Search 2, ovarin cancer 
Search 3, screening 
Combine 1 AND 2 (OR 3) and Lllv1IT by human, English, article 
Exclusion criteria* 
Multimoda1 screening investigated 
Did not report data for the outcome of interest 
Review articles 
Only specia1ized population investigated 
Total articles excluded 
Articles included from manua1 search of bibliographies 
Total studies of interest 
Combine duplicated studies from all searches 
Total articles included 
*Several of the articles met more than I of the exclusion criteria 
No. of Articles 
689 
2417 
129,948 
107 
18 
22 
40 
10 
14 
10 
107 
5 
5 
10,289 
1748 
111,564 
36 
14 
13 
4 
3 
31 
0 
5 
5 
5 
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Table 2: 24 567 Summarv of Results , · · , 
Study, Sample Outcome 
year size of 
interest 
Zurawski, 39,300 Ovarian 
1988 cancer 
Helzlsouer, ll,009 Ovarian 
I 
1993 cancer 
Einhorn, 5,550 Elevated 
1992 CA-125 
levels 
Jacobs, 9344 Ovarian 
1996 cancer 
Zurawski, 1082 Elevated 
1990 CA-125 
Table 2 (continued) 
Mean age of cases Menopausal 
at blood status 
coiJection (years) 
43,0 ± 6,8 for NIA* 
cases 
52A for cases NIA* 
56.1 ± 8.1 Unknown; 73,7% 
of cases> 50 years 
Median age - 56 NIA* 
(range 45-85) 
52± 8.5 506 post 
500 pre 
76 unknown 
Table 2 (continued) 
Type of i CA-125 
masking ! Reference value 
employed (U/mL) 
Technician only 30 
35 
Technician only 30 
35 
Technician and 30 
examining 35 
physician 
Technician and 30 
examining 50 
physician 100 
Technician and 35 
examining 65 
physician 
* Not reported by authors. 
# Calculated from values reported in study. 
o Insufficient data to calculate. 
\j1 As reported in study. 
Number Number of Number of Dropouts 
of cases controls index 
(matched) cancers 
detected 
105 323 105 N/A* 
(yes) 
37 73 37 3 cases, 
(yes) 7controls 
dropped due to 
inadequate 
matching 
175 175 9 0% of cases and 
(yes) controls; 18% 
of remaining 
sample 
49 9295 49 2,9% 
(no) 
36 36 I 2women: 
(yes) unspecified 
case/control 
status 
Source of study population Basic design of trial 
JANUS serum bank Case·control 
Washington County serum bank Case-control 
Random sample of Stockholm Prospective cohort 
Population Registry 
Volunteers recruited from Prospective cohort 
publicity campaign 
Patients undergoing physical Prospective cohort 
exam (selection process 
unknown) 
Specificity Sensitivity Relative risk PPV 
(95% Cl) 
92,6% 23,8% 3.9 (2.1-7.2) 3A%# 
95A% 17,1% 4.3 (2.1-8.8) 
912% 31.0% 6.9. (1.5-32.8) N/A o 
94.7% 2.6% 13.1 (1.6-106.6) 
95.7% NIA* NIA* NIA 0 
97.6% 
96.6% 75-47% for 35.9 (18.3-70.4) 3.1%\jl 
1·7 years of to 14.3 (8.5-
follow-up 24.3)one year to 
five years after 
screen 
97% NIA* NIA* N/A o 
99% 
t 
Table 3: Sensitivity and Specificity for a CA-125 Reference Value of35 U/mL by Menopausal Status 5 
Status #of Sensitivity Specificity Positive Negative 
cases/controls likelihood ratio* likelihood ratio* 
Premenopausal subjects 13/26 46.2% 92.3% 6.0 0.6 
Postmenopausal subjects 24/47 12.5% 97.9% 5.9 0.9 
*Not reported in study. Calculated from available data 
Table 4: Sensitivity of the CA-125 RIA as a function of time prior to diagnosis of ovarian neoplasm 4 
Time prior to diagnosis (months) N Range ofCA-1251evels (U/mL) Median CA-1251evel (U/mL) 
::S:18 12 3.7-2,413 27.2 
>18$36 16 4.4-56.3 18.2 
>36<60 18 3.4-55.7 18.0 
>60 59 3.1-142 18.3 
i 
~-
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